logo

For the Inventor, By the Inventor

Macclesfield, United Kingdom

Keith H Gibson

This inventor holds 22 USPTO granted patents and 1 published patent application, plus 1 CIPO patent, primarily in Antitumor Agents. Top assignees: Imperial Chemical Industries Limited, Astrazeneca Ab, Imperial Chemical House. Active years: 1978-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keith H Gibson. Retrieved from https://idiyas.com/inventor/keith-h-gibson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 

% Patents Active = 59.1


Average Co-Inventor Count = 2.3

ph-index = 7

Forward Citations = 222(Granted Patents)


Location History:

  • Prestbury, GB (1995 - 1996)
  • Cheshire, GB (2006 - 2009)
  • Macclesfield, GB (1978 - 2011)

Company Filing History:

goldMedal11 out of 3,840 
 
Imperial Chemical Industries Limited
 patents
silverMedal9 out of 1,534 
 
Astrazeneca Ab
 patents
bronzeMedal2 out of 2 
 
Imperial Chemical House
 patents
4. 2 out of 854 
 
Zeneca Limited
 patents
5. 1 out of 80 
 
Ici Pharma
 patents
where one patent can have more than one assignee

Years Active: 1978-2011

Loading Chart...
Loading Chart...
Areas of Expertise:
Benzamide Compounds
Quinazoline Derivatives
Antitumor Agents
Quinoline Derivatives
Therapeutic Amides
MEK Inhibitors
1,6-Naphthyridinone Derivatives
Indazole Derivatives
Prostanoic Acid Derivatives
Therapeutic Alcohols
Angiotensin II Antagonists
22 patents (USPTO):Explore Patents
1. 7897778 - Benzamide compounds (2011-03-01),
2. 7504416 - 4-substituted quinolines as antitumor agents (2009-03-17),
3. 7504408 - Quinzoline derivatives for use in the treatment of cancer (2009-03-17),
4. 7402583 - Substituted quinolines as antitumor agents (2008-07-22),
5. 7253184 - 4-Substituted quinolines as antitumor agents (2007-08-07),
6. 7173135 - Substituted 3-cyanoquinolines as MEK inhibitors (2007-02-06),
7. 7067532 - Substituted quinolines as antitumor agents (2006-06-27),
8. 6809106 - Quinoline derivatives as inhibitors of MEK enzymes (2004-10-26),
9. 6638945 - Quinoline derivatives as inhibitors of MEK enzymes (2003-10-28),
10. 5770603 - Quinazoline derivatives (1998-06-23),
11. 5684198 - Method of preparing therapeutic amides (1997-11-04),
12. 5567735 - Therapeutic amides (1996-10-22),
13. 5565477 - Therapeutic amides (1996-10-15),
14. 5565465 - Therapeutic amides (1996-10-15),
15. 5474999 - Therapeutic amides (1995-12-12),

Title: The Innovative Contributions of Keith H Gibson

Introduction

Keith H Gibson is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, holding a total of 13 patents. His work primarily focuses on the development of therapeutic compounds that address various medical conditions.

Latest Patents

Among his latest patents are innovations related to quinazoline derivatives. These derivatives are characterized by a specific formula that includes halogeno, trifluoromethyl, or (1-4C)alkyl groups. Another significant patent involves a method of preparing therapeutic amides, which are useful in treating urinary incontinence. This invention includes processes for preparing the amides and pharmaceutical compositions containing them.

Career Highlights

Throughout his career, Keith H Gibson has worked with prominent companies such as Imperial Chemical Industries Limited and Zeneca Limited. His experience in these organizations has contributed to his expertise in pharmaceutical research and development.

Collaborations

Keith has collaborated with notable individuals in his field, including Cyrus J Ohnmacht and Keith Russell. These partnerships have likely enhanced his innovative capabilities and broadened the impact of his work.

Conclusion

Keith H Gibson's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of therapeutic solutions for various medical conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…